NASDAQ:ACGN Aceragen (ACGN) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free ACGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.38▼$0.3850-Day Range$0.38▼$0.9052-Week Range$0.36▼$16.00VolumeN/AAverage VolumeN/AMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aceragen alerts: Email Address Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About Aceragen Stock (NASDAQ:ACGN)Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.Read More Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report ACGN Stock News HeadlinesAugust 26, 2023 | ca.finance.yahoo.comACGN - Aceragen, Inc.August 8, 2023 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.16%April 20, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.August 4, 2023 | finance.yahoo.comAceragen, Inc. to Delist from The Nasdaq Stock MarketJuly 12, 2023 | bizjournals.comCash-strapped public company in Durham moves to liquidate. Will shareholders get anything?July 11, 2023 | bizjournals.comInvestor wants its money back as Durham firm weighs bankruptcyJune 29, 2023 | chron.comAceragen: Q1 Earnings SnapshotMay 30, 2023 | finance.yahoo.comAceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingApril 20, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 17, 2023 | bizjournals.comDurham public company begins furloughs as it searches for capitalMarch 30, 2023 | benzinga.comAceragen Stock (NASDAQ:ACGN), Guidance and ForecastMarch 5, 2023 | barrons.comAceragen Inc.March 1, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Aceragen (ACGN)February 6, 2023 | finance.yahoo.comAceragen Announces Recommendation of Data Monitoring Committee in Terra StudySee More Headlines Receive ACGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aceragen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/19/2024Next Earnings (Estimated)7/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACGN CUSIPN/A CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$4.86 million Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.12Miscellaneous Outstanding Shares8,420,000Free Float6,196,000Market Cap$3.20 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John C. Taylor (Age 52)Pres, CEO & Director Comp: $444.06kMs. Gwen ThomasAssociate Director of HR, Fin. & Admin.Ms. Christina AmendolaDirector of HRMr. Brian JackeySr. VP of Technical OperationsMs. Deepa NagpalGlobal Head of QualityDr. Shah Rahimian M.D.Ph.D., Medical Director & Global Clinical Lead for OncologyDr. Joanna Caroline Horobin Ch.B (Age 68)M.B., Advisor Mr. Louis J. Arcudi III (Age 62)M.B.A., MBA, Adviser More ExecutivesKey CompetitorsEloxx PharmaceuticalsNASDAQ:ELOXAvalon GloboCareNASDAQ:ALBTKiromic BioPharmaNASDAQ:KRBPNanoString TechnologiesNASDAQ:NSTGQGamida CellNASDAQ:GMDAQView All CompetitorsInsidersMaxine GowenSold 51 sharesTotal: $26.01 ($0.51/share)Invest Corp PillarSold 3,605 sharesTotal: $5,695.90 ($1.58/share)Invest Corp PillarBought 26,965 shares on 5/17/2023Total: $38,290.30 ($1.42/share) ACGN Stock Analysis - Frequently Asked Questions When is Aceragen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our ACGN earnings forecast. This page (NASDAQ:ACGN) was last updated on 4/20/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTISHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent alert: open this for a huge profit potentialTimothy SykesTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsHow Biden has already won 2024Porter & CompanyTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aceragen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.